Financial Focus

• Page 1 of 10 (94 items) 1 2 3 4 5  ...  Last

• GEN Congressional Hall of Fame
  Biomedical research has friends in high places. Meet them.
• E&Y: Biotechs Must Walk the Walk on Drug Value
  In their latest annual industry report, Ernst & Young report seeing an implementation gap in how executives judge drug value vs. corporate efficiency.
• Two Roads to Wowing the Crowd
  Poliwogg eyes biopharma startups seeking millions; Microryza connects donors to researchers needing thousands.
• Is Brain Mapping Ready for Big Science?
  The BAM project will be an expensive undertaking. Will it be worth the cost?
• Funding Squeeze Traps Young Researchers
  Postdocs look beyond NIH funding as, despite policy changes, the percentage and age of first-time grant winners stay steady.
• SBIR Thinks Smaller
  New rules taking effect on January 28 aim to draw investor-owned smaller biopharmas to the federal grant program and STTR, its companion.
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
• Crossing the Valley of Death
  BioMotiv says investments in drugs and technologies, not companies, will bring treatments to market faster.
• Cliff Spells Danger for Biotechs
  If Obama and Congress cannot agree, key agencies face cuts while tax changes would dampen new investment.
• Drug Companies Exert Greater Influence on Development
  Government funding, once the norm, is declining and pharma firms are in the driver’s seat.

• Page 1 of 10 (94 items) 1 2 3 4 5  ...  Last